Loading clinical trials...
Loading clinical trials...
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT. A Dose Escalation, Open-label, Phase 1/2 Study.
Conditions
Interventions
Ex-vivo expanded γδ T cell infusion
Locations
1
China
Chinese PLA General Hospital
Beijing, China
Start Date
September 12, 2021
Primary Completion Date
April 1, 2023
Completion Date
April 1, 2025
Last Updated
March 28, 2022
NCT06285890
NCT06220162
NCT05376111
NCT04065399
NCT04628026
NCT06994676
Lead Sponsor
Chinese PLA General Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions